Roche and Defand enter molecular glue discovery collaboration targeting cancer and immune-mediated diseases

The FDA has approved Gazyva for patients aged two years and older with frequently relapsing or steroid-dependent childhood-onset idiopathic nephrotic syndrome who are in complete remission.

The collaboration gives Roche access to Atavistik Bio's AMPS platform to discover allosteric small molecules across cardiovascular, renal and metabolic disease targets.

Zealand Pharma and Roche have started the global Phase 3 ZUPREME programme evaluating once-weekly petrelintide as a treatment for people with overweight or obesity.

Roche and Dualitas Therapeutics have entered a large-scale bispecific antibody discovery collaboration potentially worth more than $1 billion across immunology and inflammation programmes.

The agreement gives Roche exclusive global rights to develop, manufacture and commercialise Simcere Zaiming's investigational trispecific antibody SIM0660 outside Greater China.

The agreement gives Genentech ex-South Korea rights to a Phase I non-incretin UCN2 analogue designed to reduce weight while preserving lean body mass, adding a differentiated mechanism to Roche’s growing cardiometabolic pipeline.

The Elecsys IGRA TB test delivers results in under 24 hours and brings automated latent tuberculosis screening to Roche's cobas immunoassay platforms.

Genentech has secured global rights to a fragment-based drug discovery programme targeting a key regulator of breast cancer cell growth.

Roche has struck a deal worth up to $2.3bn with Nurix Therapeutics to co-develop and co-commercialise bexobrutideg (NX-5948), an oral BTK degrader targeting B-cell malignancies, immunology, and neurology.

Landmark decision ties bladder cancer treatment to molecular residual disease testing